comparemela.com

Faisal Khurshid News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Eli Lilly makes small buy of cancer drugmaker — the payoff comes later

Point Bio Prostate Cancer Therapy Meets Phase 3 Goal, But Results Still Disappoint

Despite achieving its Phase 3 study's main goal, the results for Point Biopharma's therapy are short of what Novartis radiopharmaceutical Pluvicto achieved in a similarly designed clinical trial. Nevertheless, the data readout should clear the way for Eli Lilly to complete its $1.4 billion acquisition of Point.

Point radiopharma drug results disappoint in prostate cancer study

Point Biopharma stock nearly doubles on Eli Lilly deal

Point Biopharma stock nearly doubles on Eli Lilly deal
invezz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from invezz.com Daily Mail and Mail on Sunday newspapers.

PNT Stock Launches 84% On Eli Lilly s $1 4 Billion Takeover | Investor s Business Daily

PNT Stock Launches 84% On Eli Lilly s $1 4 Billion Takeover | Investor s Business Daily
investors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investors.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.